Abstract. The development of functional blood and lymphatic vessels requires spatio-temporal coordination of the production and release of growth factors such as vas-
Introduction
Angiogenesis, the formation of new blood vessels from preexisting ones, is a complex and tightly regulated process. The development of fully functional vessels requires spatio-temporal coordination of the production, release and deposition in the extracellular matrix (ECM) of several growth factors such as vascular endothelial growth factors (VEGFs), angiopoietins, transforming growth factor-β, fibroblast growth factor and platelet-derived growth factor (PDGF) by many cell types (reviewed in [1] [2] [3] ). This process is counterbalanced by angiogenesis inhibitors such as ECM-derived polypeptides or specific inhibitory molecules like PEDF [4, 5] . Impaired vessel function is associated with many pathologies, for instance in atherosclerosis [6] , diabetic retinopathy [7, 8] , arthritis [9] , malignant cell growth [10] [11] [12] , neurodegenerative disease such as amyotrophic lateral sclerosis (ALS) [10, 13] and in preeclampsia, a placental insufficiency observed in some patients in the late stage of pregnancy
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A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2 [14] . These disorders arise from mutation or impaired expression of various signaling molecules regulating angiogenesis, in particular of angiogenic growth factors such as VEGFs and their receptors that directly operate on endothelial cells. VEGFs regulate physiological and pathological angiogenesis and belong to a gene family that includes VEGF-A, -B, -C, -D [3] , placenta growth factor (PlGF) [15] , orf virus-encoded VEGF-like proteins called VEGF-E [16] [17] [18] and a series of snake venoms collectively called VEGF-F [19] [20] [21] [22] . VEGF family growth factors form cysteine cross-linked dimers folded into a cysteine knot structure [23] . All mammalian VEGFs are produced in multiple isoforms upon alternative splicing and proteolytic processing giving rise to a plethora of functionally divergent proteins [24, 25] . Although structurally very similar, the different VEGFs display distinct properties and bind to specific subtypes of VEGF receptors. VEGFs are produced by normal and transformed cells upon exposure to hypoxia [26, 27] and promote endothelial cell growth, migration and survival, but also regulate blood vessel permeability and vasodilation (reviewed in [10] ). The importance of VEGF in vascular development has been documented in knockout mice where disruption of a single allele of the VEGF-A gene leads to embryonic lethality [28, 29] . Even subtle changes in VEGF expression during fetal development [28, 30] , a block in the expression of a particular VEGF-A splice variant [31] or disruption of one allele of the gene encoding VEGFR-2 result in abnormal blood vessel formation and are embryonic lethal [33] . VEGF is also important for tumor growth; blocking VEGF with antibodies, soluble receptor or inhibiting VEGF receptor kinase activity have shown promising clinical results in tumor therapy [10] . In mammals VEGF-A is expressed in many variants upon alternative splicing of a single precursor mRNA. Four major splice variants, VEGF-A 121 , VEGF-A 165 , VEGF-A 189 and VEGF-A 206 have been described [34, 35] . The longer isoforms show binding affinity to the ECM, particularly to heparan sulfate glycosaminoglycans (HSPG), while VEGF-A 121 is a soluble, acidic polypeptide that does not interact with HSPG [35] . The longer versions of VEGF-A bind to additional receptors such as neuropilin-1 and -2, which play a role in cell adhesion and in nerve and vessel guidance [36] [37] [38] . Increased activation of VEGFR-2 in the presence of heparan sulfate (HS) and neuropilin-1 or -2 has been observed for VEGF-A 165 , the isoform most prominently expressed in mammals [37] [38] [39] . The most basic VEGF variant, VEGF-A 189 , is sequestered in the ECM and shows no biological activity unless mobilized by heparinases, while VEGF-A 206 is proteolytically cleaved and released from the ECM by metalloproteinases. Recently, new VEGF-A splice variants have been described which carry an alternative C terminus encoded by exon 9 instead of exon 8 [40, 41] . The best characterized member of these proteins is VEGF 165 b which was isolated from kidney epithelial cells. This protein showed anti-angiogenic properties counteracting VEGF-A 165 in vitro and in vivo. VEGFs signal through cell surface receptor tyrosine kinases related to the PDGF receptor family. VEGF-A binds to both VEGF receptor 1 (VEGFR-1) and -2 (VEGFR-2) [3, 10] , while PlGF and VEGF-B exclusively bind to VEGFR-1 [42] [43] [44] .VEGF-C and VEGF-D are specific ligands for VEGFR-2 and VEGFR-3, which regulate both blood and lymphatic vessel development [45] .Viral VEGF-Es and some snake venom VEGF-F variants exclusively activate VEGFR-2 [18] [19] [20] .
Here we study the biological activity of VEGF-A 165 b in which the C-terminal domain encoded by exon 8 was replaced by an exon 9-encoded sequence. This protein binds VEGF receptors with the same affinity as VEGF-A 165 , shows reduced binding to HS, does not bind neuropilin-1 and displays altered signaling properties through VEGFR-2 and ERK kinases. Cloning and expression of VEGFs. The methylotrophic yeast Pichia pastoris was used to express all VEGF isoforms. Our constructs were derived from the canine isoform of VEGF-A, which is shorter by one amino acid than the human isoforms [48] . The exon 8 encoded sequence (Cys Asp Lys Pro Arg Arg) was replaced by the sequence Ser Leu Thr Arg Lys Asp encoded by human exon 9. All expression vectors were constructed by the PCR subcloning method [49] with the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) using pPICZαAVEGF-A 165 , a vector for expression of VEGF-A 165 in Pichia pastoris [48] , as template. The following primers were used in the first PCR reaction: VEGF-A 165 b primer 1: 5′-GCGACTGGTTCCAATTG ACAAG-3′, VEGF-A 165 b primer 2: 5′-GATGATGATGATGTCGACT-CATCAGTCTTTCCTGGTGAGAGATCTGCAAG-TAGTTCGTTTAACTCAAG-3′, VEGF-A 159 primer 1: 5′-GCGACTGGTTCCAATTGACAAG-3′ and VEGF-A 159 primer 2: 5′-GATGATGATGATGGTCGAATCATCTG-CAAGTACGTTCGTTTAACTC-3′. The constructs were linearized with SacI and transferred into Pichia pastoris strain X-33 by electroporation (Easyselect TM Pichia Expression Kit, Invitrogen). Clones were selected for protein expression (Easyselect TM Pichia Expression Kit, Invitrogen). The proteins were produced in a 3.7 l fermenter (Bioengineering, Wald, Switzerland) as described [46] .
Materials and methods

Materials
Purification of VEGF-A 165 b and VEGF-A 159 .
Proteins were affinity purified with an ÄKTAprime TM system (GE Healthcare). Cell-free medium was collected from yeast cultures, sterile filtered through 0.45-μm MF TM membrane filters (Millipore, Billerica, MA, USA) and concentrated to 200 ml by ultrafiltration (Schleicher & Schuell GmbH, Dassel, Germany). Buffer was exchanged with binding buffer (20 mM sodium phosphate, pH 7.4, 0.5 M NaCl and 10 mM imidazole) and loaded onto a 50-ml Ni 2+ -NTA column (GE Healthcare) equilibrated with binding buffer. The material was eluted by gradually increasing the imidazole concentration to 500 mM. The peak fractions were analyzed by SDS-PAGE, pooled, concentrated using a YM 10 ultrafiltration membrane (Millipore) and dialyzed overnight at 4 °C against PBS.
Radioiodination and cell binding assays. 125 Iodine labeling of recombinant VEGF-A 165 was performed with the IODO-GEN method according to the Pierce protocol (Pierce, Rockford, IL, USA). Briefly, 0.5 mCi Na 125 I (IMS-30, GE Healthcare) was activated for 6 min at room temperature (RT) by incubation in a tube coated with 50 μg iodogen and mixed with a solution containing 10 μg VEGF-A 165 for 9 min at RT. The reaction was stopped with 1 mM DTT and the iodinated protein was separated from free iodine on a PD10 gel filtration column (GE Healthcare) equilibrated with 0.5% BSA, 1 mM citric acid in PBS. The specific radioactivity of VEGF-A 165 was 62 000 cpm/ng. PAE cells expressing VEGFR-1 or VEGFR-2 or VEGFR-2 together with neuropilin-1 were grown overnight to subconfluency in 24-well tissue culture plates and incubated for 4 h at 4 °C with 0.1 nM 125 Ilabeled VEGF-A 165 with or without the indicated amount of cold competitor. Each data point was determined in triplicate. Unbound radioactive protein was washed off with MEM-HBS, 25 mM HEPES, with or without Lglutamine (Amimed, Allschwil, Switzerland) containing 0.25% BSA. Cells were then lysed in 200 μl 1 M NaOH and radioactivity determined in a Beckman γ counter.
In vivo chicken embryo chorioallantoic membrane (CAM) assay and histological analysis of CAMs. Protein (1 μg) was applied to a 0.5% methylcellulose carrier placed onto the CAM of shell-free grown chicken embryos (Lohman LSL strain, Animalco, Staufen, Switzerland) at embryonic day 8. Angiogenesis was monitored for up to 4 days after sample application under a stereomicroscope and pictures were taken. A solution of 20% Lipovenös (Fresenius Kabi, Stans, Switzerland) was injected into the CAM immediately before photographing to improve the contrast. For histological analysis, CAMs were fixed in 3.5% formaldehyde at 4 °C. Areas to be analyzed were cut out and washed in PBS for 30 min at 4 °C. Samples were incubated for 30 min at RT in 0.85% NaCl, rinsed twice in 50% EtOH in 0.85% NaCl, then in 70% EtOH in PBS for 20 min at RT and embedded in paraffin. Sections were deparaffinized in xylene and stained with hematoxylin (Medite AG, Nunningen, Switzerland) and eosin (Chroma-Gesellschaft, Münster, Germany). Average pixel intensities of digitized pictures were quantified with ImageJ software (NIH, Bethesda, MD, USA).
In vivo chamber implant angiogenesis assay. Sterile tissue chambers made of perfluoro-alkoxy-Teflon ® were filled with 500 μl molten 0.8% w/v agar containing 20 U/ml heparin (Novo Nordisk A/S, Bagsvaerd, Denmark) with or without growth factor (46 or 92 nM) and implanted aseptically into female mice (FVB) (Charles River Laboratories, les Oncins, France). Four days after implantation, chambers were recovered from the animals and the vascularized tissue that had formed around each implant was removed and weighed. Tissue samples were homogenized in RIPA buffer (50 mM Tris-HCl, 121 mM NaCl, 1 mM EDTA, 6 mM EGTA, 1% NP-40, 20 mM NaF, 1 mM Pefabloc SC, 1 mM Na 3 VO 4 ). Samples were then centrifuged for 1 h at 7000 rpm. The supernatant was filtered using a 0.45-µm syringe filter (Acrodisc ® GF, Gelman Sciences, Ann Arbor, MI, USA) to avoid fat contamination. The amount of hemoglobin present in the filtrate was determined spectrophotometrically at 540 nm using a Drabkin reagent kit (Sigma). For Tie-2 determination Nunc maxisorb 96-well plates were coated overnight at 4 °C with the capture anti-Tie-2 antibody (Upstate Inc., Charlottesville, VA, USA) at a concentration of 2 μg/ml. Wells were washed three times with Tris phosphate-buffered saline (TPBS) and blocked by incubating with 3% Top-Block (Juro, Lucerne, Switzerland) for 2 h. Wells were then washed three times with TPBS and protein lysates were added for 2 h. After washing, a complex of anti-Tie-2 antibody (R&D Systems) and alkaline phosphatase conjugated anti-goat antibody (Pierce Biotechnology) was applied for 1 h at RT. After washing three times with TPBS, Tie-2 antibody complexes were detected by incubating with p-nitrophenyl phosphate (4-NPP) (Sigma) and the absorbance was determined in an ELISA reader at 405 nm. Recombinant human extracellular domain of Tie-2 fused to the constant region of human IgG1 dissolved in RIPA buffer was used as standard.
Heparin affinity chromatography. VEGF was applied to a 1 ml HiTrap heparin HP column (GE Healthcare) equilibrated with varying salt concentrations in 20 mM Tris (pH 7). VEGF was eluted with a linear salt gradient reaching a final concentration of 1.2 M and column fractions were monitored on an ÄKTA prime system (GE Healthcare) operated at a flow rate of 1 ml/min.
Neuropilin-1 binding in ELISA.
Nunc microtiter plates were coated overnight at 4 °C with 2.8 μg/ml recombinant neuropilin-1 (R&D Systems). Plates were washed twice with PBS and blocked in PBS containing 2% BSA for 1 h at 37 °C. Unspecific binding was determined on duplicate plates treated with 2% BSA in PBS. After washing, the different VEGF isoforms were added to the wells at the indicated concentrations, followed by a 1 h incubation at 37 °C. After washing with PBS, bound VEGF was detected using a mixture of monoclonal anti-VEGF (R&D Systems) and alkaline phosphatase conjugated anti-mouse antibody. Plates were rinsed three times with Tris-buffered saline (20 mM Tris/HCl, pH 7.5, 150 mM NaCl, TBS) and alkaline phosphatase activity was determined colorimetrically with 4-NPP, absorbance at 410 nm was quantified in an ELISA reader.
Immunoprecipitation and in vitro immune complex kinase assays. VEGFR-2 activity was determined in Western blots using a phospho-specific antibody directed against Y1175 of VEGFR-2 (Cell Signaling . Quantification of the data was performed with ImageQuant software (Molecular Dynamics, GE Healthcare). The films were scanned and the ratio of the intensities of the bands corresponding to the pY1175 and the MBP signal, respectively, were corrected for the intensity of the bands reflecting the total amount of VEGFR-2 and ERK-1 and -2, respectively. (Fig. 1b) . These results demonstrate that the sequence encoded by exon 8 is not required for binding to VEGF receptors 1 and 2 and that the exon 9 variant showed identical binding to VEGF receptors as the exon 8 isoform.
Results
VEGF production and purification. All VEGFs were produced in the yeast
In vivo angiogenesis. A simple experimental system to qualitatively evaluate the angiogenic potential of growth factors in vivo is the chicken CAM. Samples (1 μg) of each VEGF variant were applied to the CAM of an 8-dayold chicken embryo and vascularization in the area of application evaluated 48 h later. Compared with PBS controls (average pixel intensity ± SD, 138 ± 13), where no alteration of the vascular network was seen, VEGF-A 165 induced a network of microvessels giving the CAM in this area a reddish color (average pixel intensity 149 ± 27, Fig. 2a ). Average pixel intensities for VEGF-A 165 b and VEGF-A 159 were 138 ± 17 and 138 ± 14, respectively. Histological examination of hematoxylin and eosinstained paraffin sections shows that capillaries are only located in the chorionic epithelium and that the stroma is avascular in PBS controls. VEGF-A 165 -treated CAMs displayed highly vascularized stroma with a large number of erythrocytes, while CAMs treated with VEGF-A 165 b or VEGF-A 159 showed only few vessels (Fig. 2b) . These results suggest that the C-terminal domain encoded by exon 8 is required for full biological activity of VEGF-A 165 . The exact role that exon 8 plays in VEGF-mediated vascularization remains at present unknown. We next implanted a chamber containing an agarose/ heparin matrix loaded with VEGF under the skin of a mouse. As shown in Figure 3 antagonized VEGF-A 165 when both proteins were simultaneously added in equimolar amounts reminiscent of earlier described data [41] and 21%, respectively, of the material bound to the column. In the absence of NaCl, all proteins containing the exon 7, but lacking the exon 8 sequence, weakly bound to the column, while VEGF 121 did not bind heparin at all (data not shown). These data show that VEGF-A lacking exon 8 shows drastically reduced affinity for heparin, suggesting that the C-terminal exon 8-encoded sequence is essential for interaction with HS. HS binding does not, therefore, solely depend on sequences encoded by exon 7 as described before. The longer isoforms of VEGF family proteins also bind to neuropilins, a class of cell surface receptors involved in many biological processes [55] . This interaction has been shown to be mediated by the exon 7 domain of VEGF-A [56] . We next determined binding of the various VEGF-A isoforms to recombinant neuropilin-1. As shown in Fig (Fig. 4b) . These data were confirmed on PAE cells expressing VEGFR-2 together with neuropilin-1. As shown in Figure 4c , only exon 8 containing VEGF-A completely competed binding of VEGF 165 . Our data therefore suggest that sequences encoded by exon 7 are not sufficient for HS and neuropilin-1 binding to VEGF-A and thus reveal a role for the exon 8 sequence in these interactions.
VEGF-A 165 b shows delayed and attenuated signal output through VEGFR-2. We next assessed the signaling properties of VEGF-A 165 and VEGF-A 165 b using a phospho-specific antibody against pY1175 of VEGFR-2 as shown in Figure 5a . Receptor stimulation by VEGF-A 165 b was delayed, less robust and more transient than with VEGF-A 165 . One of the primary signaling pathways activated by VEGFR-2 is signaling via MAP kinases such as ERK-1 and -2 that regulate cell migration, survival, mitogenesis and cell differentiation. Earlier results suggest that the extent and the kinetics with which receptor tyrosine kinases activate MAP family kinases are of pivotal importance for the biological output elicited by a particular ligand [57] [58] [59] . We, therefore, studied the time course of ERK-1 and -2 activation in two types of endothelial cells derived from pig aorta (PAEC) and bovine aorta (BAEC). We found robust and sustained activation of ERK-1 and -2 by VEGF-A 165 , while VEGF-A 165 b promoted only weak and blunted activation (Fig. 5b) . The predominant MAP kinase activated in endothelial cells was ERK-2. In cells treated with VEGF-A 165 ERK-2 activity was two-to threefold lower than in controls treated for 15 min with fetal calf serum (lanes F in Figure 5b ) and was up to tenfold lower in cells treated with VEGF-A 165 b (Fig. 5b) . A quantification of a series of experiments is given in Table 1 . In all experiments VEGF-A 165 b showed significantly lower activity at all time points. From these data, we conclude that the C-terminal domain of VEGF-A encoded by exon 8 determines the kinetics and the strength of signal output by VEGFR-2.
Discussion
The discovery of new VEGF-A splice variants by Bates and coworkers has raised interesting questions concerning the role of the C-terminal domain encoded by exon 8 of VEGF-A 165 in receptor activation. The biological activity of this splice variant was initially described in tumor cells expressing VEGF-A 165 b, which showed drastically reduced malignancy in vivo when compared with VEGF-A 165 expressing cells [40, 41] . Putative exon 9 variants of VEGF-A can be deduced from the mouse, human, dog, bovine, monkey, quail and zebrafish DNA sequence [41] (and our own unpublished work). The exon 9 encoded sequence is not conserved among these species, while the rest of the protein sequence is highly conserved. This indicates that the specific biological function of VEGF-A 165 b might predominantly derive from the absence of exon 8 and not from the acquisition of new functionalities encoded by exon 9. The phenotype of VEGF-A 159 , a mutant that was made to assess whether exon 9 is directly responsible for the biological activity of VEGF-A 165 b, or whether the absence of exon 8 was sufficient, was, however, not clear. In some assays, VEGF-A 159 was similar to VEGF-A 165 b, in others it behaved like VEGF-A 165 . Replacing exon 8 by exon 9 resulted therefore in a more drastic phenotype than exon 8 deletion. Without detailed structural information for VEGF-A 165 b such data are difficult to interpret. So far only the structures of a C-terminally truncated form of VEGF-A [60] and of the exon 7 and 8 encoded heparin binding domain have been solved [61] . This latter NMR structure shows that cysteine 146 forms an intramolecular disulfide bond with cysteine 160, restricting the flexibility of this domain and stabiliz- Table 1 . ing a patch of basic amino acids exposed on the surface of this protein. The functional significance of this disulfide bond is further documented by a VEGF-A mutant in which cysteine 146 was changed to a serine residue [62] and which had reduced activity. Taken together, our data show that the sequence encoded by exon 8 is part of the heparin and neuropilin-1 binding domains and/or is mandatory for their proper folding. VEGF-A mutants lacking cysteine 160 may assume a more flexible structure, resulting in reduced affinity for HSPG and preventing binding to neuropilin-1. Additional mutagenesis of exon 8 will help to elucidate the exact role that this domain plays in VEGF-A mediated receptor activation. All VEGF-A variants lacking exon 8 studied here bound VEGF receptors 1 and 2 with the same affinity as VEGF-A 165 . On the other hand, mutants lacking exon 8 only weakly bound HS and did not bind to neuropilin-1 at all. Expression in endothelial cells of neuropilin-1, a plexin family protein that also interacts with semaphorins and plays an essential role in both neural guidance and vessel development, has been shown to enhance binding of VEGF-A 165 to VEGFR-2 [37, 53, 63] . This was attributed to the b1b2 domain of neuropilin-1 that interacts with the exon 7 and 8 encoded C terminus of VEGF-A 165 [64] . The importance of neuropilin-1 for the development of functional vessels is well documented in knockout animals [65] . Using in vivo angiogenesis animal models we show that VEGF-A 165 b has reduced biological activity and even inhibits angiogenic signaling when used together with VEGF-A 165 . VEGF-A 165 b also elicited significantly weaker signal output through VEGFR-2 and ERK kinases. This further documents that binding to HSPG and neuropilin-1 is not only required for the deposition and storage of VEGF-A 165 in the ECM and on neuropilin-1-expressing cells, but that these interactions have also a direct impact on receptor signaling. VEGF-A 165 leads to robust and sustained activation of VEGFR-2, while signaling via VEGFR-2 by the exon 9 variant is weak, shows delayed kinetics, and is only transient. Such differences might result from the distinct structure of ligand/receptor complexes, and suggest that only VEGF-A 165 is capable of fully activating the receptor and its downstream signaling pathways. Co-ligation of VEGFR-2 with HSPG and/or neuropilin-1, resulting in delayed receptor desensitization by phosphatases and attenuated receptor degradation similar to recently published work on HSPG/VEGFR-2 complexes is a possible explanation for this phenomenon [66] . Coordinated expression of soluble and ECM-bound VEGF-A are indispensable for the development of functional vascular networks. Neuropilin-1-expressing cells might further support this process by sequestering VEGF-A, thereby contributing to the ordered deposition of this protein in the vascular bed. Based on our data we propose that HSPGs and/or neuropilin-1 fulfill an additional role by directly modulating VEGF-mediated receptor activation. Exon 8 VEGF-A splice variants show features that are typical for partial receptor agonists; they bind VEGF receptors with identical affinity as fully functional ligands yet elicit attenuated signal output. The biological role that VEGF-A isoforms lacking exon 8 play in vivo during vessel development remains at present unclear and must be addressed in transgenic animals.
